Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Belite Bio Inc ADR (BLTE)

Belite Bio Inc ADR (BLTE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,107,662
  • Shares Outstanding, K 29,149
  • Annual Sales, $ 0 K
  • Annual Income, $ -31,630 K
  • 60-Month Beta -1.62
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 11.29
Trade BLTE with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.34
  • Number of Estimates 2
  • High Estimate -0.27
  • Low Estimate -0.40
  • Prior Year -0.33
  • Growth Rate Est. (year over year) -3.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.00 +28.21%
on 04/17/24
43.45 -8.52%
on 03/27/24
-3.73 (-8.58%)
since 03/26/24
3-Month
31.00 +28.21%
on 04/17/24
48.60 -18.21%
on 02/12/24
-5.85 (-12.83%)
since 01/26/24
52-Week
11.00 +261.36%
on 06/23/23
48.60 -18.21%
on 02/12/24
+10.28 (+34.88%)
since 04/26/23

Most Recent Stories

More News
Why Shares of Belite Bio Soared This Week

The clinical-stage biotech company bounced back from a 52-week low late last week.

AMD : 157.40 (+2.37%)
BLTE : 39.75 (+4.61%)
Why Shares of Belite Bio Are Slumping Wednesday

The biopharmaceutical company announced a stock sale that's not great news to current investors.

AMD : 157.40 (+2.37%)
BLTE : 39.75 (+4.61%)
3 Breakout Growth Stocks to Buy for the Long Haul

These three have had big-time share gains backed up by breakthrough science.

BLTE : 39.75 (+4.61%)
TMDX : 92.08 (+3.17%)
RYTM : 38.28 (+0.34%)
2 Stocks Up 165% and 209% in 2022 That Could Keep Soaring in 2023

Find out how these stock rockets could continue their ascent.

BLTE : 39.75 (+4.61%)
TMDX : 92.08 (+3.17%)
3 Soaring Biotech Stocks That Could Climb Much Higher

These drugmakers have bucked the overall market's downward trend this year and expectations are still high.

BLTE : 39.75 (+4.61%)
CINC : 29.06 (-0.48%)
PLRX : 11.81 (-0.59%)
Small-Cap Catalyst Pharma Is Among Market's Best Price Performers

Small-cap biotech Catalyst Pharmaceuticals has been outperforming the broader market amid earnings and revenue acceleration. It joined the S&P 600 last month.

SPSM : 41.11 (+0.61%)
CPRX : 14.89 (+1.43%)
CG : 46.11 (+1.07%)
APLS : 49.86 (+4.03%)
AERI : 15.25 (+0.07%)
BLTE : 39.75 (+4.61%)
VRNA : 15.47 (+1.05%)
RVNC : 3.40 (+3.34%)
Belite Bio Reports First Half 2022 Operational Highlights and Financial Results

 -LBS-008 (aka Tinlarebant) is Belite Bio’s orally administered tablet for the treatment of Stargardt disease (STGD1) and Dry AMD -A 2-year Phase 2 trial...

BLTE : 39.75 (+4.61%)
Belite Bio to Host Conference Call on August 11, 2022 to Discuss First Half 2022 Financial Results

SAN DIEGO, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company...

BLTE : 39.75 (+4.61%)
Belite Bio Submits Investigational New Drug (IND) Application to FDA for Approval to Proceed with LBS-008 Phase 3 Clinical Trial for the Treatment of Stargardt Disease

LBS-008 (a/k/a Tinlarebant) is the Company’s orally administered tablet for the treatment of Stargardt disease (STGD1)There are currently no approved...

BLTE : 39.75 (+4.61%)
Belite Bio Announces Partial Exercise of Over-Allotment Option in Initial Public Offering

SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug...

BLTE : 39.75 (+4.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Belite Bio Inc. is a clinical stage biopharmaceutical drug development company focused on novel therapeutics targeting currently untreatable eye diseases involving retinal degeneration, such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease, and metabolic diseases....

See More

Key Turning Points

3rd Resistance Point 42.72
2nd Resistance Point 41.47
1st Resistance Point 40.61
Last Price 39.75
1st Support Level 38.50
2nd Support Level 37.25
3rd Support Level 36.39

See More

52-Week High 48.60
Last Price 39.75
Fibonacci 61.8% 34.24
Fibonacci 50% 29.80
Fibonacci 38.2% 25.36
52-Week Low 11.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar